治疗药物监测
伏立康唑
医学
重症监护医学
白霉素类
抗真菌
协调
抗真菌药
药物治疗
药品
药理学
临床实习
药代动力学
两性霉素B
抗真菌药
梅德林
米卡芬金
治疗方法
治疗指标
棘白菌素
卡斯波芬金
治疗效果
侵袭性念珠菌病
作者
Jessica Cusato,Alessia Cafaro,Sara Cairoli,Giuliana Cangemi,Dario Cattaneo,Antonello Di Paolo,Pierantonio Menna,Raffaele Simeoli,Massimo Tempestilli,Bianca Maria Goffredo,on behalf of the SIBioC Working Group “Therapeutic Drug Monitoring e Personalizzazione della Terapia”
标识
DOI:10.1097/ftd.0000000000001539
摘要
BACKGROUND: Invasive fungal infections are associated with high morbidity and mortality, particularly among immunocompromised and critically ill patients. Antifungal therapy is complicated by substantial pharmacokinetic variability, drug-drug interactions, and narrow therapeutic windows for some agents. Although therapeutic drug monitoring (TDM) can optimize drug exposure, therapeutic targets vary across studies and guidelines. The aim of this review was to provide an updated overview of antifungal TDM and support the harmonization of therapeutic ranges based on pharmacokinetic/pharmacodynamic (PK/PD) evidence. METHODS: A comprehensive search of major literature databases and international guidelines was conducted through November 2025 to identify studies reporting antifungal therapeutic targets and clinical applications of TDM. When therapeutic ranges differed across studies or guidelines, alternative targets were reported, considering the clinical settings and populations in which they were proposed. RESULTS: Robust evidence supports routine TDM for triazoles with high pharmacokinetic variability, particularly voriconazole and posaconazole, for which target trough concentrations are well established and associated with clinical outcomes. For isavuconazole, routine TDM is not universally recommended but may benefit selected high-risk populations, including critically ill, pediatric, and obese patients and those receiving extracorporeal therapies. Conversely, routine TDM is not currently recommended for echinocandins or amphotericin B because of limited exposure-response data, although emerging evidence suggests that TDM may be useful in selected clinical scenarios. Variability in PK/PD targets, analytical methods, and preanalytical factors contributes to inconsistent implementation in clinical practice. CONCLUSIONS: Harmonization of antifungal therapeutic ranges is essential to improve the clinical utility of TDM and support individualized antifungal therapy. Further studies are required to establish standardized targets for all antifungal classes.
科研通智能强力驱动
Strongly Powered by AbleSci AI